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Abstract: Infection with human immunodeficiency virus remains a global concern with a 
significant number of incident infections still reported worldwide. The use of prophylaxis prior 
to exposure to the virus to prevent infection has been a growing area of recent research. Results 
in nonhuman primates and clinical trials in high-risk patient populations using preexposure 
prophylaxis have shown promising results in terms of efficacy and safety, especially relating to 
oral preexposure prophylaxis. The potential use of oral antiretroviral agents traditionally used 
for human immunodeficiency virus treatment as prophylaxis raises interesting considerations, 
such as the best agents available for such a role, long-term safety in healthy individuals, and 
the potential development of resistance to these agents should infection occur. From a public 
health perspective, the cost-effectiveness of implementing this preventive strategy has not been 
fully defined at this point in time.
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Introduction
Human immunodeficiency virus (HIV) remains a significant public health challenge. 
There are currently more than 33 million people living with acquired immune defi-
ciency syndrome (AIDS) worldwide.1 Despite increasing access to antiretroviral drugs, 
the Joint United Nations Program on HIV/AIDS reported a total of 2.7 million new 
infections worldwide in 2008.1
Efforts to curb transmission by treating HIV-infected patients in serodiscordant 
couples2,3 and prophylaxis to prevent mother-to-child transmission4 have likely played 
a significant role in decreasing incident infections. But these measures, along with 
longstanding public health measures, have not been able to prevent incident infections. 
In the United States, for example, there are an estimated 56,000 cases of incident 
HIV infections per year.5,6 Men who have sex with men (MSM) account for 53% of 
these cases.
In order to decrease these incident infections, new strategies for preventing HIV 
transmission, especially among high-risk groups, have emerged. Preexposure pro-
phylaxis (PreP), one of these approaches, involves the use of topical or oral agents 
in HIV-uninfected individuals prior to exposure to the virus in order to prevent HIV 
acquisition. In addition, PreP may potentially play a role in attenuating the natural his-
tory of HIV disease progression in patients who become infected, reducing morbidity 
and decreasing infectiousness to others.7
In this review, the current knowledge regarding the use of topical and oral agents 
for PreP will be presented. The ideal pharmacokinetics for efficacy of PreP agents, 
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and the results of preclinical animal models and human 
clinical trials of PreP will be discussed. Additionally, the 
debate regarding the long-term safety of PreP, the implica-
tions of developing resistant HIV on PreP, and the overall 
cost-effectiveness of implementing PreP as a prevention 
strategy will be explored. 
Microbicides
Microbicides are topical products that can be applied to either 
the vaginal or rectal mucosa to prevent HIV transmission. 
The idea for microbicides developed as a means by which 
women could have control over their risk of HIV infec-
tion and potentially prevent other sexually transmitted 
infections.8,9 Research in the field grew as the percent-
age of women infected with HIV increased, especially 
in Sub-Saharan Africa, where 67% of the HIV-infected 
individuals worldwide live.1
Unfortunately, over the past decade, research into vari-
ous microbicides has not yielded compelling data for their 
efficacy. Clinical trials of surfactants, agents that disrupt 
the cell membranes of viruses and bacteria, and polyanions 
(eg, Carraguard® cellulose sulfate, PRO 2000) showed prom-
ise in in vitro and in animal studies,10–13 but did not show 
statistically significant differences between rates of HIV 
acquisition in clinical trials.14–19 In fact, nonoxynol-9 and 
cellulose sulfate were associated with an increased risk of 
HIV acquisition in women, likely due to a rapid and sustained 
reduction in transepithelial resistance.20,21
Due to the lack of efficacy of these microbicides, focus 
has shifted toward agents that might be more specific for HIV . 
Tenofovir (TDF), a nucleotide analog that blocks the reverse 
transcription of HIV in the host cell, has been studied as a 
microbicide in a 1% gel form, both by itself and in combi-
nation with emtricitabine (FTC), another nucleoside analog 
that comes in a 5% gel.20 These agents have been chosen for 
their long half-lives (TDF: .60 hours, FTC: ∼40 hours), 
allowing them to persist in tissues long after extracellular 
concentrations decline.
Studies of macaques exposed to simian immunodefi-
ciency virus (SIV) and simian-human immunodeficiency 
virus (SHIV) vaginally and rectally have been used as animal 
models for studying HIV acquisition. One study revealed that 
a 1% TDF gel applied rectally to rhesus macaques offered a 
statistically significant partial efficacy against SIV .22 In one 
study, the vaginal application of 1% TDF alone or in com-
bination with 5% FTC two times per week fully   protected 
macaques from a total of 20 exposures to homologous 
SHIV .23 These studies are further outlined in Table 1.
Building on these animal models, the Center for the 
AIDS Programme of Research in South Africa 004 clinical 
study,24 a double-blind randomized controlled trial of about 
900 South African HIV-uninfected higher-risk women ages 
18–40, compared rates of HIV acquisition with TDF gel 
versus   placebo gel. The HIV incidence in the TDF gel arm 
was 5.6 per 100 women years compared with 9.1 per 100 in 
the placebo arm, which was statistically significant. In those 
with .80% adherence, the HIV incidence was 54% lower 
in the TDF gel arm. Although there was documented effi-
cacy, low rates of adverse reactions, and no documentation 
of resistance to TDF developing in women who acquired 
HIV , rates of HIV transmission were still high. Therefore, 
this strategy needs to be used in conjunction with other 
preventive strategies, such as condoms, in order for it to be 
fully beneficial.
Other antiretroviral microbicides currently in multiple 
phase I and II clinical trials are dapivirine and UC 781, two 
non-nucleoside reverse-transcriptase inhibitors (NNRTIs).25,26 
From data available, both seem to attain high levels in 
cervicovaginal fluid, although their efficacy remains to be 
evaluated in further clinical trials. The safety of these agents 
in the more delicate epithelium of the rectum is now being 
studied. A phase I trial of UC781 revealed no significant 
adverse events and no significant plasma levels in sexually 
abstinent men and women applying the microbicide rec-
tally during single and 7-day exposures.27 Phase III clinical 
trials evaluating the efficacy of the dapivirine ring, IPM 009A 
and IPM 009B, will commence shortly.28
Antagonists to C–C chemokine receptor type 5 (CCR5), 
the chemokine co-receptor for HIV entry into the cell, have 
also been effective as microbicides in macaque studies,29,30 
as well as in humanized monoclonal mouse models.31 See 
Table 1 for further details of the macaque studies.
From the data available, the lack of systemic absorption of 
antiretroviral microbicides appears to prevent problems with 
resistance developing in patients that are using them while 
unknowingly infected, and safety trials have not revealed any 
significant adverse reactions.14 However, microbicides do not 
protect against other sexually transmitted infections, which 
can also facilitate HIV acquisition.32 Therefore, antiretroviral 
microbicides likely will be most effective when used with 
barrier protection. The use of such microbicides to prevent 
rectal transmission in both men and women is still under 
investigation.
Microbicides by themselves are not likely to have a 
si  gnificant impact on decreasing the incidence of HIV   globally. 
Poor adherence, lower efficacy rates and increased cost 
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c  ompared to condoms are significant dr  awbacks. In the 
Center for the AIDS Programme of Research in South Africa 
004 trial, 41% of women exhibited low adherence, defined 
as using the gel ,50% during intercourse.24 In day-to-day 
use outside of a clinical trial, one would expect this number 
to be even lower, thereby compromising the benefits of this 
intervention.
Oral prophylaxis
Theoretical considerations  
with preexposure prophylaxis
The use of oral antiretroviral drugs as PreP has a founda-
tion in existing knowledge. These agents have been used in 
preventing perinatal transmission of HIV4 and acquisition of 
the virus after percutaneous occupational exposures.33
It is critical to understand the pathogenesis of HIV in 
order to understand why PreP works. After exposure to HIV , 
systemic infection usually does not occur immediately, but 
is delayed 1–3 days.34 During this period, a small population 
of “founder cells” appear to be responsible for spreading 
the infection to a cluster of nearby cells, which then leads to 
viral dissemination and systemic viremia as early as 5 days 
after exposure.34,35 The administration of antiretrovirals for 
PreP when populations of founder cells are being established 
may disrupt the infection cycle and help the immune system 
eradicate the virus.
The choice of an ideal agent for oral PreP is depen-
dent on multiple factors including: (1) whether it acts 
pre-integration or post-integration (2) the pharmacoki-
netics of the agent, including its ability to achieve high 
concentrations in   cervicovaginal fluid and the rectum, (3) 
barriers to resistance, (4) pill burden, and (5) safety and 
tolerability.
An agent with activity against HIV prior to its establishment 
in the host cell (ie, pre-integration) would be ideal for use as 
PreP because it would prevent the establishment of HIV infec-
tion in cells. Protease inhibitors are post-integration agents, 
and their use in this field will likely be limited, although cur-
rently there is no available data to support this assertion.
Additionally, the optimal PreP should have ideal phar-
macokinetic properties, including rapid distribution and 
long half-life into tissues. FTC and TDF, for example, both 
have long intracellular half-lives (40–100 hours), with rapid 
distribution into tissues, and achieve high concentrations 
in the cervicovaginal fluid.36,37 Studies measuring levels 
of antiretrovirals in cervicovaginal fluid have shown that 
NRTIs achieve the highest levels when compared to protease 
inhibitors and NNRTIs.37 More recent data has revealed 
high concentrations of both maraviroc, a CCR5 antagonist, 
and raltegravir, an integrase inhibitor, in both the male and 
female genital tracts.38–41 Maraviroc has also achieved high 
rectal concentration in healthy men.38 See Figure 1 for a 
comparison of these agents and their concentration in the 
genital tract relative to blood.
Of the antiretroviral agents mentioned, NRTIs and CCR5 
antagonists are the most appealing for PreP for the reasons 
already cited, as well as for their high barrier to resistance and 
relatively good safety profile. Maraviroc is currently a twice-
daily medication, which is a drawback that might hinder 
larger trials looking at its efficacy for PreP. However, it is 
unclear whether or not maraviroc could be given once daily 
for prevention instead of treatment and this needs further 
0
Tenofovir
Emtricitabine
Lamivudine
Abacavir*
Zidovudine
Maraviroc
Raltegravir
100 200 300 400 500 600 700
Concentration in female genital tract
relative to blood (in percent)
Concentration in male genital tract
relative to blood (in percent)
Figure 1 Concentration of select oral antiretrovirals in the genital tract of men and women relative to blood.
Adapted from references 35–40.
Notes: In general, the nucleoside reverse transcriptase inhibitors seem to concentrate better in the genital tract of men and women than protease inhibitors and non-
nucleoside reverse transcriptase inhibitors (the latter two are excluded from this graph). Some more recent data, although there was significant variability between subjects, 
shows that raltegravir and maraviroc each can achieve significant levels as well. 
*Abacavir achieves lower levels in the female genital tract relative to blood (∼40%).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
20
Majid et alHIV/AIDS - Research and Palliative Care 2012:4
study. Given that CCR5-tropic viruses represent the majority 
of transmitted viruses, maraviroc may have a unique niche 
in PreP since it does not form the backbone of current anti-
retroviral regimens as do the NRTIs.
Once-a-day integrase inhibitors, which block viral inte-
gration into the host cell, have been developed.42,43 Despite 
their pre-integration efficacy, integrase inhibitors are not 
ideal, given their low barrier to resistance, which makes their 
long-term efficacy questionable. The pharmacokinetics of 
these agents have also not been as well studied.
For these reasons, the majority of animal studies and 
clinical trials studying PreP have looked at agents like TDF 
or FTC/TDF, although oral maraviroc may have a potential 
role for prophylaxis, which will be discussed.
Preclinical animal studies of PreP
Both macaque and mouse models have been used to study 
the potential efficacy of PreP, mainly using TDF and FTC. 
In macaque monkeys, SIV and SHIV have been used as 
nonhuman primate models to mimic human immunodefi-
ciency virus. SHIV more closely mimics the various aspects 
of human infection.
Data from the macaque monkey trials with oral antiret-
rovirals is summarized in Table 2.44–50 Initially, studies in 
SIV focused on a single agent, TDF, which showed efficacy 
at preventing SIV44 but, at oral doses comparable to human 
doses, only revealed partial efficacy at preventing SHIV 
infection.45,46 This prompted many of the most recent animal 
studies and human clinical trials to look at the combination 
of FTC/TDF.
In general, the macaque studies have shown that the 
combination of FTC/TDF can be very effective in prevent-
ing the acquisition of SIV and SHIV after oral, rectal, or 
vaginal exposure. Increased efficacy seems to correlate with 
increased dosages of antiretrovirals. One study utilizing 
intermittent weekly dosing of subcutaneous TDF and FTC 
before and after viral exposure showed equivalent protection 
from SHIV infection as provided by the same medications 
given daily.47 This study provides a potential foundation 
for human clinical trials looking at intermittent PreP. The 
macaque studies have also demonstrated that the use of an 
oral CCR5 antagonist, CMPD167, can protect a substantial 
portion of macaques from infection with a CCR5-using 
SHIV virus.50
Humanized mouse models that harbor HIV-susceptible 
human cells have also been used to examine PreP. Studies 
using this model have demonstrated the efficacy of TDF 
and FTC/TDF in preventing vaginal, rectal, and intravenous 
transmission of HIV .51,52 One study used this model and 
demonstrated that oral raltegravir and maraviroc protected 
against a vaginal HIV-1 challenge.53
Clinical studies
The data from animal studies, as well as the success of 
antiretrovirals in preventing mother-to-child transmission 
and postexposure prophylaxis after occupational exposure, 
has prompted many clinical trials looking at the use of PreP 
in high-risk HIV populations. To date, these trials have all 
evaluated the efficacy of either TDF or FTC/TDF.
The first published clinical report of PreP compared daily 
TDF versus placebo in 936 West African women from Ghana, 
Cameroon, and Nigeria in preventing HIV transmission via 
vaginal intercourse.54 Two women in the TDF group and six 
women in the placebo group became infected, but this result 
was not statistically significant. The study terminated early 
due to the closure of two of the clinical sites, which limited 
the planned person-years of follow-up and the power of the 
study.
The Preexposure Prophylaxis Initiative (iPrEx) study,55 
a subsequent landmark multinational study, evaluated the 
safety and efficacy of FTC/TDF in 2499 HIV seronegative 
men or transgender women who have sex with men, a group 
with a high number of incident infections worldwide. One 
hundred patients became infected during follow-up, 36 in 
the FTC/TDF group and 64 in the placebo group, indicat-
ing a statistically significant 44% prevention efficacy. In 
subgroup analyses, efficacy was higher among subjects 
that reported that they had previously had unprotected 
receptive anal intercourse and those that reported greater 
than 90% compliance with pill use. Of those patients in 
the FTC/TDF group that became infected with HIV, only 
three had detectable levels of drug in their blood, none with 
cell-associated drug levels higher than the median levels 
for seronegative controls.
Preliminary data from additional clinical trials has yielded 
conflicting data in other high-risk groups. The TDF2 study56 
followed 1200 heterosexual men and women in Botswana ran-
domized to receive FTC/TDF versus placebo, and found a sig-
nificantly decreased risk of HIV acquisition (nine patients in 
the FTC/TDF arm as opposed to 24 patients in placebo). As 
women are one of the main target groups for PreP, it is impor-
tant to note that the protective effects of FTC/TDF were seen 
in both women and men, although the study was underpowered 
to evaluate sex-based   differences. These results are in contrast 
to the FEM-PrEP trial, a phase III clinical trial of oral FTC/
TDF in nearly 2000 women at high risk for HIV infection. 
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This study was ended prematurely early in April of 2011 
after a preliminary review of the data revealed equal rates of 
infections in the TDF and placebo groups.57 The study was 
deemed unlikely to be able to demonstrate efficacy if contin-
ued, and the study is being reviewed to assess the reasons for 
this surprising result.
Another phase III trial, the Partners PreP study,58 com-
pared TDF, FTC/TDF, and placebo in preventing HIV 
transmission in HIV-discordant heterosexual African couples. 
Both the TDF and FTC/TDF arms had a statistically signifi-
cant decreased incidence of HIV infections versus placebo, 
with a 62% HIV protection efficacy noted in the TDF arm and 
a 73% protection efficacy noted in the FTC/TDF group.
Like the Partners study, the results of HPTN 052, 
although not a PreP trial, support the efficacy of early anti-
retroviral drugs in reducing rates of sexual transmission of 
HIV-1 among serodiscordant couples.59 In this multinational 
study of 1763 couples, the HIV-infected partners were ran-
domized to receive early antiretroviral therapy or delayed 
treatment once CD4 criteria were met. Only one of the 28 
overall partner-linked infections occurred in the group that 
was randomized to receive early antiretroviral therapy, which 
was statistically significant.
The discrepancy between the FEM-PreP trial and the 
other clinical trials in African countries showing the clinical 
efficacy of FTC/TDF is worth discussing. The most plausible 
explanation is that the subjects in FEM-PreP had lower 
adherence than they self-reported. The measurement of 
serum levels and the tissue concentration of these drugs are 
a better means of assessing adherence than self-reporting. 
There may be other factors that we do not yet understand in 
the FEM-PreP population that, even with reasonable adher-
ence, might contribute to decreased levels of antiretrovirals 
systemically and, more importantly, in the cervicovaginal 
fluid. A recent study, for example, revealed significantly 
lower levels of tenofovir diphosphate in the vaginal tissue 
of patients receiving oral tenofovir as opposed to vaginally 
applied tenofovir.60 Achieving levels of active drug in the 
cervicovaginal tissue is a valid concern, although it does not 
fully explain the discrepancy between the various studies. 
The data from the FEM-PreP trial is being analyzed by its 
investigators to better try to identify the reason for the dis-
cordant results in this study compared to others.
With a small number of clinical trials completed showing 
the efficacy and relative safety of oral PreP with FTC/TDF 
in high-risk groups for infection with HIV, further studies 
are in progress.61 These include studies of MSM, high-risk 
women, and injection drug users, and evaluate strategies 
for intermittent PreP. Information on phase II and phase III 
clinical trials of oral PreP are found in Table 2. One of these 
trials, the Vaginal and Oral Interventions to Control the 
Epidemic (VOICE) study, aimed to compare the efficacy of 
oral tenofovir, oral truvada, and vaginal tenofovir as PreP 
to each other and to placebo.63 During interim reviews by 
an independent safety board, the trial discontinued both the 
oral tenofovir arm and the vaginal gel arm since review of 
the early data indicated lack of efficacy of either compared 
to placebo.63 Potential explanations for the lack of efficacy of 
oral tenofovir include the varying degrees of active tenofovir 
drug in the cervical tissue of women when administered in 
an oral formulation and intermittent or poor adherence.60
Mathematical models have examined PreP and seen 
the potential for a significant public health benefit to its 
implementation, both in the United States and developing 
countries. With a product demonstrating 90% efficacy and 
with 75% coverage of the general population, models forecast 
a 74% decline in the number of cumulative HIV infections 
in 10 years.64 These models are encouraging, but do not fac-
tor in some of the important considerations with regard to 
safety, the development of resistance to PreP medications, 
and potential changes in sexual-risk behavior over time, 
considerations that will be discussed.
Considerations for the long-term 
use of PreP
Safety
Most of the clinical trials looking at the use of FTC/TDF for 
PreP seem to indicate that use for over a year seems relatively 
safe. The CAPRISA trial demonstrated that no statistically 
significant adverse reaction was seen more frequently in the 
TDF gel group compared to placebo.24 With regards to oral 
PreP, the iPrEx study revealed that the only significant adverse 
reactions encountered by subjects were nausea and weight 
loss, with a trend observed of elevated creatinine levels in the 
FTC/TDF group that was not clinically significant.55 It should 
be noted, however, that the majority of this study population 
was less than 40 years old. As with populations that tend 
to make up clinical trials, one could also presume that they 
would have been a healthier population than the real-world 
population that would be using these medications. Patients 
using PreP, therefore, may encounter more side effects or 
drug–drug interactions than could be expected within the 
confines of a study. Another important consideration is that 
we have extensive knowledge about the side-effect profile of 
FTC/TDF, but there is the potential that medication use in a 
patient population with an intact immune system could lead 
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to unforeseen side effects, as we have seen previously with 
hepatotoxicity developing in patients with high CD4 counts 
starting nevirapine.65
Safety information available from the Partners PrEP 
study, the study of West African women, the United States 
Extended Safety Trial, and the TDF2 study of heterosexual 
men and women in Botswana all seem to demonstrate short-
term safety of PreP. The Partners PreP prophylaxis trial, for 
example, only showed increased diarrhea with active agents.61 
According to the Centers for Disease Control, preliminary 
data from the US Extended Safety Trial (CDC 4323) of 400 
MSM receiving oral tenofovir as PreP also did not raise 
significant safety concerns.66
None of the longer-term cumulative toxicities have 
been addressed by the clinical trials to date. The trend to 
an elevated creatinine in the iPrEx with less than perfect 
adherence study raises concerns for cumulative toxicities 
including renal failure, tubulointerstitial disease, electrolyte 
derangements, bone disease, and potential flares of 
hepatitis B that should not be underestimated. Recently 
presented and published data has demonstrated reductions 
in bone mineral density in seronegative men participating in 
clinical trials with TDF and FTC/TDF.67,68 In the tenofovir 
PreP study among MSM in San Francisco, a statistically 
significant decline in bone mineral density in the femoral 
neck and hip was seen compared to placebo. The implica-
tions for bone health over longer periods of time in a PreP 
setting need to be studied further, but one would expect 
further deteriorations in both health and clinically signifi-
cant fractures over time.
One area of safety that has been discussed, but not studied 
extensively, is the impact of the use of TDF and FTC/TDF in 
cases of hepatitis B co-infection where the patient is unaware 
of their hepatitis status. In the TDF trial of West African 
women, this side effect was not seen. But given the activity of 
TDF and FTC/TDF against hepatitis B, the incidence of hepa-
titis B flares, and the development of hepatitis B resistance to 
these medications, further investigation is required.
Resistance
One of the biggest concerns with HIV PreP is the develop-
ment of resistance to these medications in those who become 
infected. Especially in the developing world, resistance to 
first- and second-line regimens has significant implications 
for treatment options for HIV-infected patients. FTC and TDF 
are two of the most potent and well-tolerated medications used 
worldwide for HIV treatment, and we cannot lose the ability 
to prescribe these medications for the treatment of HIV .
FTC has signature resistance mutations at codon 184 
with a single nucleotide change that result in amino acid 
changes from methionine to isoleucine (M184I) or valine 
(M184V).69,70 Either of these mutations confers a high level of 
resistance to either FTC or lamivudine (3TC).71 Monotherapy 
studies have shown that M184V mutations can develop 
within approximately 15 days of treatment with lamivudine.70 
Despite the high level of resistance to these medications, 
studies have shown that their continuation in regimens does 
confer a benefit with regard to viral suppression, likely due to 
decreased replicative capacity of the virus.71,72 Additionally, 
hypersusceptibility to other components of an antiretroviral 
regimen can occur with these mutations (eg, TDF,   zidovudine 
[AZT]).73 One animal macaque study exemplified this point 
by showing that rectal transmission of an FTC-resistant 
isolate with an M184V mutation did not occur in macaques 
receiving prophylaxis with FTC/TDF, although it did occur 
in all of the controls.49
There are two specific mutations that influence the effi-
cacy of tenofovir: K65R and K70E/G. The K65R mutation 
involves a change at the second nucleotide codon position from 
lysine to arginine and causes intermediate-level resistance to 
tenofovir.74,75 There is some data to support that this mutation 
is more likely to occur in patients with subtype C of HIV , the 
prevalent subtype seen in Sub-Saharan Africa and India, that 
are not fully suppressed on their antiretroviral regimen.76,77 
Single nucleotide alterations in codon 70 lead to an amino acid 
shift from lysine to glutamate and a second transition required 
to yield glycine. This produces decreased susceptibility to 
tenofovir and other antiretrovirals, including FTC. Mutations 
associated with TDF do not occur as rapidly as the 184V/I 
with FTC, with monotherapy studies predicting development 
of these mutations in the 4- to 8-week timeframe.78,79
Dual therapy with FTC/TDF in patients who are intermit-
tently adherent to these medications will likely lead to the 
development of an M184V mutation within several weeks, 
with almost all patients exhibiting resistance within a year.73,80 
In the iPrEx study, two of the men had seronegative HIV 
infection at the time they started to receive active drug, and 
both were noted to have M184V mutations by week 4.55 
In the TDF2 study, one participant had unrecognized HIV 
infection and was subsequently found to develop resistance 
to both FTC and TDF.54 In an area like southern Africa, 
where the C subtype of HIV predominates, one might expect 
higher rates of TDF resistance to develop. It will, therefore, 
be interesting to see the resistance mutations that develop 
with longer-term follow-up, especially in the trials based in 
Sub-Saharan Africa.
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An M184V mutation in a patient in the developing world 
can have significant implications for treatment, since most 
first-line regimens involve two NRTIs (usually a combination 
of TDF or AZT and lamivudine or FTC) with an NNRTI. 
Although the M184V virus would exhibit hypersusceptibility 
to TDF or AZT and would be less fit for replication, a regi-
men based on one active NRTI and an NNRTI, given the low 
barrier to resistance of the NNRTI, runs the risk of treatment 
failure. One mathematical model looking to predict the effect 
of PreP on the HIV epidemic in MSM in San Francisco 
forecasts decreased transmission of HIV , but an increased 
proportion of new infections caused by resistant strains.81
Outside a clinical trial, one could expect more resistant 
mutations to develop due to poorer adherence and compli-
ance with follow-up. In order to avoid the consequences for 
resistance in patients on a partially suppressive antiretroviral 
regimen with undiagnosed infection, regular HIV testing 
should be linked to the use of PreP. The development of an 
infrastructure to provide HIV testing at least every 6 months 
in subjects receiving PreP is critical to prevent resistance with 
implementation of PreP.
Cost-effectiveness and considerations  
for the implementation of PreP
The high cost of implementation of PreP is an important 
consideration in its potential adoption as a prevention strategy 
in high-risk populations. The wholesale cost of FTC/TDF 
is about US$900 per month, not factoring in other costs, 
including personnel and infrastructure costs, counseling, 
routine testing, and surveillance for adverse reactions.82 
Using data from the iPrEx study, it is estimated that about 
44 people would have to receive PreP to prevent one infec-
tion, which reflects a cost of over $500,000 over a 1-year 
period.83 This cost is about 20 times the amount that it takes 
to treat someone with HIV for a year. In this model, PreP is 
not cost-effective.
It is also unlikely that these medications for PreP will be 
covered by private insurance, which leaves public financing 
as the only option for implementing a PreP program. With 
the current economic downturn, public funding may not 
be readily available. Some state drug assistance programs 
set up to treat individuals already infected with HIV are 
running out of resources, with large waiting lists for anti-
retroviral treatment. In resource-limited settings, it would 
seemingly be more difficult to set up the infrastructure 
for a PreP program and to garner the funds for such an 
endeavor when there are not sufficient funds to treat indi-
viduals already infected with HIV. Currently, the World 
Health Organization does not even mandate treatment for 
  HIV-infected partners in   serodiscordant couples, despite 
the results of the HIV Prevention Trials Network 052 study 
which demonstrated that treatment of the HIV-infected 
partner in serodiscordant couples has a significant impact 
on decreasing transmission of HIV .59
Aside from the lack of cost-effectiveness of a PreP 
strategy, there are other important public health and population 
considerations for implementation. This includes the optimal 
target group for treatment (high-risk MSM participating in 
receptive anal intercourse, female and male sex workers). 
Which practitioners would be in a position to offer PreP? 
What training would they require? Also, one would need to 
decide whether to use a daily-pill strategy or an intermittent-
pill strategy, the latter model showing efficacy in animal 
models but not yet in humans.
PreP may have implications on an individual level as 
well. Concerns have been raised that the availability of PreP 
may lead to more risky sexual practices through behavioral 
disinhibition, also known as risk compensation.84 The concept 
is that people might feel protected by PreP and stop using 
barrier methods of protection, which have been proven to be 
more efficacious. Risk compensation has not yet been seen in 
placebo-controlled clinical trials, although some data exists 
that it is a genuine concern in high-risk populations.85 The 
attitudes of high-risk individuals to PreP, actual levels of 
adherence, and the role of risk compensation need to be stud-
ied further. In the clinical trials of PreP already completed, 
other preventive strategies for decreasing HIV transmission 
are reinforced to subjects as part of the study protocol. It is 
not yet clear whether or not these same measures would be 
built into a program for PreP in a real-world setting.
Future areas of interest
The role of PreP as a strategy that can be widely imple-
mented for HIV prevention remains to be determined. From 
a research standpoint, there are other drugs and molecules 
that could be and are being evaluated in clinical studies for 
PreP, including CCR5 antagonists. Biologic molecules that 
have an effect on CCR5 expression could potentially be 
another area of interest that will help avoid the concerns 
about antiretroviral drug resistance.
Despite the data that has demonstrated the efficacy of 
PreP in higher-risk populations, there are many unknown 
factors with regards to longer-term use of oral antiretrovirals 
for PreP, including safety and resistance concerns. Equally 
important, there are significant public health concerns relat-
ing to the implementation of such a strategy. PreP needs to 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
25
Preexposure prophylaxis for HIVHIV/AIDS - Research and Palliative Care 2012:4
be evaluated alone and in combination with other approaches 
such as universal testing and early treatment of HIV infec-
tions to determine the best means to decrease the incidence 
of HIV infections worldwide.
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